<DOC>
	<DOCNO>NCT00001062</DOCNO>
	<brief_summary>To determine whether alternate oral ganciclovir intravenous ( IV ) ganciclovir prevent relapse Cytomegalovirus ( CMV ) retinitis improve quality life AIDS patient . A systemic treatment strategy CMV retinitis need effective yet convenient administer , without need permanent indwell IV catheter . Although oral ganciclovir use maintenance follow induction IV ganciclovir , patient reactivation disease must reinduced IV . A fixed-schedule regimen oral IV ganciclovir alternate may prevent reactivation progression disease , oppose current therapeutic strategy change therapy event-driven . Also , duration intermittent IV therapy require control disease may short enough eliminate need indwell catheter .</brief_summary>
	<brief_title>A Study Ganciclovir Treatment Cytomegalovirus Eyes</brief_title>
	<detailed_description>A systemic treatment strategy CMV retinitis need effective yet convenient administer , without need permanent indwell IV catheter . Although oral ganciclovir use maintenance follow induction IV ganciclovir , patient reactivation disease must reinduced IV . A fixed-schedule regimen oral IV ganciclovir alternate may prevent reactivation progression disease , oppose current therapeutic strategy change therapy event-driven . Also , duration intermittent IV therapy require control disease may short enough eliminate need indwell catheter . Patients receive IV induction ganciclovir 2 week follow alternate course 3 week oral ganciclovir 1 week IV drug four cycle ( 16 week ) . If CMV retinitis fail arrest initial induction , IV ganciclovir administer additional 2 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Erythropoietin , GCSF , GMCSF . Antiretrovirals . Patients must : HIV infection . Evaluable CMV retinitis photographable lesion . Life expectancy least 6 month . No active AIDSdefining opportunistic infection malignancy require nephrotoxic myelosuppressive therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Evidence retinal vascular relate infectious disease retinal lesion would interfere ability detect response therapy progression . Corneal , lens , vitreous opacification preclude funduscopic exam . Clinically significant pulmonary neurologic impairment seizure disorder CNS mass lesion . Inability obtain temporary IV access . Requirement permanent catheter IV ganciclovir administration . Uncontrolled diarrhea nausea prevent ingestion medicine . Known hypersensitivity IV oral ganciclovir . Concurrent Medication : Excluded : Immunomodulators . Biologic response modifier . Interferon . Related investigational agent . CMV prophylaxis . Systemic acyclovir . Any nephrotoxic agent . Any concomitant therapy would prohibit use ganciclovir . Prior Medication : Excluded : Prior treatment CMV retinitis . More 4 month prior ganciclovir foscarnet , within 4 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Cytomegalovirus Retinitis</keyword>
</DOC>